A Phase 1 interventional study of lenalidomide and bortezomib in Plasma Cell Myeloma, sponsored by Sanofi. Completed at 12 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-29.
Sponsored by Sanofi · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.
Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 14th largest by enrollment, is one of 4 that started in 2015, is one of 10 in phase 1, and was the 4th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18–75
Natalie Callander · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
By country, each count listing its studies:
isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 31 · Phase 3 11
First in 2013; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 55 across the 50 interventional studies. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 50 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
39 studies in Multiple Myeloma by Sanofi: 3 open now, 8 under way, 3 of them phase 3. Of 30 finished, 12 (40%) have results posted.
Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 12th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2015, is one of 10 in phase 1, and was the 21st registered.
Sanofi’s Multiple Myeloma studies by the year they started, since 2002.
9 of the studies testing isatuximab in Multiple Myeloma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT06517017University of UtahUse of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma | 2026-11 |
| NCT06832865Massachusetts General HospitalELISA in Relapsed/Refractory MM | 2026-12-01 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 50 studies testing isatuximab in Multiple Myeloma, from their registry updates:
Among Sanofi’s 39 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
VCDI cohort:
VRDI Part A cohort and Part B cohort:
Secondary Objectives:
VCDI cohort:
VRDI Part A cohort and Part B cohort:
The duration of the study for an individual patient will include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Newly diagnosed patients with measurable multiple myeloma defined as at least one of the following:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VCDI cohort: Isatuximab (escalating dose) + bortezomib + cyclophosphamide + dexamethasone (VCDI): Induction phase will be 50 weeks (12 cycles). The duration of a cycle will be 42 days (6 weeks) for Cycle 1 (C1) and 28 days (4 weeks) for subsequent cycles. The duration of a cycle of the maintenance phase will be 28 days (4 weeks). After C12, isatuximab will be administered at its initial assigned dose and dexamethasone once every 28 days. VRDI cohort parts A and B: Isatuximab + bortezomib + dexamethasone + lenalidomide (VRDI): Induction phase will be 24 weeks (4 cycles at 6 weeks/cycle). The duration of a cycle of the maintenance phase will be 28 days (4 weeks). Maintenance therapy may continue until disease progression, unacceptable AE or patient willingness to discontinue. VRDI Part A: Enrollment to begin after the VCDI cohort is completed. VRDI Part B: Enrollment to begin after the VRDI part A is completed.
Drug: lenalidomide · Drug: bortezomib · Drug: cyclophosphamide · Drug: dexamethasone · Drug: isatuximab SAR650984
Pharmaceutical form: tablet Route of administration: oral
Also known as: Revlimid
Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous
Also known as: Velcade
Pharmaceutical form: tablet Route of administration: oral
Also known as: Endoxan
Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Sarclisa
Assessment of dose-limiting toxicities (DLTs) in VCDI cohort
Time frame: Up to 6 weeks per treated patient
Overall response rate (VCDI)
Time frame: Up to 34 weeks of treatment (induction phase)
Complete response rate (VCDI)
Time frame: Up to 34 weeks of treatment (induction phase)
Complete response rate (VRDI)
Time frame: Up to 104 weeks of treatment (induction and maintenance phase) in VRDI part A and part B cohorts
Number of patients with adverse events (AEs), clinically significant changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling
Time frame: VCDI: Up to approximately 106 weeks, VRDI Part A and Part B: Up to approximately 104 weeks
Overall response rate (VRDI)
Time frame: Up to 104 weeks of treatment (induction and maintenance phase) in VRDI part A and part B cohorts
Infusion duration
Time frame: VRDI Part B: Up to 104 weeks of treatment
Assessment of PK parameter: Partial area under the serum concentration time curve (AUC)
Time frame: VCDI: Up to approximately 42 weeks, VRDI: Up to approximately 48 weeks
Assessment of PK parameter: Maximum observed concentration (Cmax)
Time frame: VCDI: Up to approximately 42 weeks, VRDI: Up to approximately 48 weeks
Levels of human antidrug antibodies (ADA)
Time frame: VCDI: Up to approximately 42 weeks, VRDI: Up to approximately 48 weeks
Duration of response - time
Time frame: VCDI and VRDI: Until treatment discontinuation by the last patient
Progression-free survival for VCDI
Time frame: VCDI: 30 months after LPI
Progression-free survival for VRDI
Time frame: VRDI Part A and Part B: 24 months after LPI
MRD negativity rate
Time frame: Up to 3 years of treatment (induction and maintenance phase) in VRDI part A and part B cohorts
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Sep 2015 to primary completion in Jan 2022, 75 months.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 75 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab